Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of Pipecuronium with Sugammadex
NCT07044193Phase 4Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of pipecuronium in neuromuscular blockade (NMB) (2 arms). Primary endpoint: Time till TOF ratio of 0.9. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
pipecuronium
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07044193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044193.